(MENAFN- GlobeNewsWire - Nasdaq) Opportunities center on AI- and cloud-based biosimulation, precision medicine and virtual trials, with rising adoption of PK/PD modeling, predictive toxicology and simulation-as-a-service.Dublin, Sept. 14, 2026 (GLOBE NEWSWIRE) -- "Biosimulation Market Report 2026" has been added to ResearchAndMarkets.com's offering.
Global Biosimulation Market to Reach $11.11 Billion by 2030 as AI and Virtual Clinical Trials Transform Drug Development
The global biosimulation market is experiencing rapid growth as pharmaceutical and biotechnology organizations increase their use of computational modeling, predictive analytics, and virtual clinical trials. The market is projected to expand from $4.98 billion in 2025 to $5.84 billion in 2026, representing a compound annual growth rate (CAGR) of 17.3%.
Historical market growth has been supported by expanding pharmaceutical research and development activity, the increasing complexity of biological systems research, wider adoption of computational modeling in drug development, greater regulatory acceptance of simulation data, and improved access to advanced computing resources. Biosimulation software and services are increasingly being integrated across drug discovery, preclinical research, clinical development, and regulatory submission processes.
The biosimulation market is forecast to reach $11.11 billion by 2030, growing at a CAGR of 17.5% from 2026. Key growth drivers include rising demand for precision medicine modeling, greater investment in artificial intelligence-powered biosimulation tools, expansion of in silico clinical trials, pressure to shorten drug development timelines, and increasing adoption of cloud-based biosimulation platforms.
Prominent biosimulation market trends include the growing use of model-based drug development, pharmacokinetic and pharmacodynamic simulation platforms, virtual clinical trial technologies, disease modeling applications, and predictive toxicology solutions. These technologies help researchers evaluate potential therapies, refine dosing strategies, assess safety risks, and improve clinical study design before advancing candidates into costly trials.
Rising global healthcare expenditure is also expected to support biosimulation market growth. Greater demand for advanced medical treatments, aging populations, and sustained investment in innovative drug development are encouraging pharmaceutical companies and research institutions to adopt simulation technologies. These platforms can support predictive disease modeling, virtual studies, and data-driven therapeutic decisions while improving the efficiency of research programs.
In April 2025, the American Medical Association reported that United States healthcare spending reached $4.87 trillion in 2023, an increase of 7.5% year over year and approximately $14,570 per person. Continued healthcare investment is expected to accelerate demand for biosimulation software and services that can reduce development risk, optimize resource allocation, and support faster delivery of new therapies.
Technology providers are prioritizing advanced pharmacokinetic-pharmacodynamic modeling platforms to improve predictive accuracy and streamline drug development. In August 2024, Certara introduced Phoenix version 8.5, an upgraded platform supporting PK-PD modeling, population simulations, clinical trial forecasting, enhanced data analysis, visualization, and scenario testing. The platform is designed to strengthen therapeutic decision-making and help researchers optimize clinical study design.
Strategic acquisitions are further shaping the competitive landscape. In January 2023, Certara acquired Vyasa Analytics for an undisclosed amount. The transaction expanded Certara's biosimulation capabilities through the addition of deep learning and data fabric technologies, supporting the continued integration of artificial intelligence into drug discovery and development workflows.
The biosimulation market includes software and services used for molecular modeling, pharmacokinetic and pharmacodynamic analysis, toxicity prediction, physiologically based pharmacokinetic modeling, trial design, drug discovery, and drug development. Key end users include pharmaceutical and biotechnology companies, contract research organizations, regulatory authorities, and academic research institutions.
North America was the largest region in the biosimulation market in 2025, while Asia-Pacific is expected to record the fastest growth during the forecast period. The regions covered include Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. Countries covered include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the United Kingdom, the United States, Canada, Italy, and Spain.
Markets Covered:
1) By Product: Software; Services
2) By Application: Drug Development; Drug Discovery; Other Applications
3) By End User: Pharmaceutical And Biotechnology Companies; Contract Research Organizations (CROs); Academic Research Institutions; Other End Users
Subsegments:
1) By Software: Pharmacokinetics (PK) Simulation Software; Pharmacodynamics (PD) Simulation Software; Toxicology Simulation Software; Disease Modeling Software; Integrated Biosimulation Platforms
2) By Services: Consulting Services; Model Development Services; Data Analysis And Interpretation Services; Training And Support Services; Custom Simulation Services
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Key Attributes:
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment